Retatrutide 32 Pen
Pre-filled research pen containing 32mg of Retatrutide, a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. For research purposes only.
BodyPharm UAE supplies Retatrutide 32 Pen for research purposes across Dubai, Abu Dhabi, Sharjah, and the wider UAE. All compounds are sourced to strict purity standards and shipped with secure, trackable delivery.
Research Areas
Designed for advanced research in these areas
Metabolic pathway modulation studies
Body composition and energy expenditure research
Appetite signalling mechanism analysis
Multi-receptor agonist pharmacology
Certificate of Analysis
Verified by independent & in-house laboratory testing
Janoshik Analytical
Third-party laboratory
Report
#106564
Batch
RET4683
Purity
99.409%
Received
06 Feb 2026
In-House Testing
Body Pharm laboratory
Report
#20251011
Batch
RET3254
Purity
98.75%
Concentration
14.06 mg/ml
Precision Engineered
Retatrutide is a novel investigational triple-agonist peptide that simultaneously targets GIP, GLP-1, and glucagon receptors. It is being studied for its potential role in metabolic regulation, energy expenditure modulation, and body composition research. Its multi-receptor mechanism of action has made it a compound of significant interest in preclinical and clinical metabolic research settings.
Research Background
Retatrutide (LY3437943) engages three metabolic receptors at once: GIPR, GLP-1R, and the glucagon receptor (GCGR). The glucagon component draws the most research interest, since GCGR activation is associated in laboratory models with hepatic glucose output, thermogenesis, and changes in hepatic fat fraction relevant to NAFLD/MASH studies.
Phase 2 data published in The New England Journal of Medicine (2023) is the most cited reference for its metabolic profile. Supplied for in vitro and laboratory research only; not for human use.
Frequently Asked Questions
Retatrutide (LY3437943) is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. For laboratory research only.
BodyPharm sells Retatrutide strictly for research purposes. Customers are responsible for understanding applicable regulations in their jurisdiction.
Phase 2 data in NEJM (2023) reported a mean body weight reduction of about 17.5% at 24 weeks at the highest studied dose, plus reductions in hepatic fat fraction relevant to NAFLD/MASH research.
Refrigerated at 2 to 8 degrees Celsius, away from heat, light, and repeated freeze-thaw cycles.
One pre-filled Retatrutide 32 Pen, packaged for refrigerated transport. The batch matches a Certificate of Analysis published on the lab results page.
What Researchers Say
How was our customer service? Did your delivery arrive on time? Was the product what you expected? Let us know and receive 10% off and free delivery with your next order.
Specifications
Premium-grade formulation for advanced research
32mg
Total Content
≥99%
Purity
Pre-filled Research Pen
Format
2-8°C Refrigerated
Storage
0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg
Volume Options
Retatrutide
Active Ingredient
Retatrutide (LY3437943)
Compound Name
2381089-83-2
CAS Number
~4731 g/mol
Molecular Weight
HPLC (Janoshik)
Verification
Ready to order?
Retatrutide 32 Pen
AED 1,750
Same day delivery across the UAE